Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Neoplasms × Exenatide × 90 days × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 35 130-nm albumin-bound paclitaxel 20 pembrolizumab 18 Specimen Handling 18 Magnetic Resonance Spectroscopy 17 Fluorouracil 16 Leucovorin 15 Irinotecan 15 Taxes 14 Oxaliplatin 14 Albumin-Bound Paclitaxel 14 Biopsy 13 Cyclophosphamide 10 fludarabine 9 Carboplatin 7 dehydroftorafur 6 Cetuximab 6 olaparib 5 Radiosurgery 5 defactinib 4 aldesleukin 4 Radiotherapy 4 Pancreatectomy 4 Cisplatin 4 trastuzumab deruxtecan 3 niraparib 3 irinotecan sucrosofate 3 atezolizumab 3 Pemetrexed 3 Nivolumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-03-19

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡